T CELL RECEPTOR AFFINITY VIA FREE ENERGY MINIMIZATION

通过自由能最小化实现 T 细胞受体亲和力

• 批准号: 2867459
• 负责人: Zhiping Weng
• 金额: $ 9.99万
• 依托单位: PHARMADYNE, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-30 至 2000-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2867459
• 关键词: T cell receptor; computer program /software; computer simulation; computer system design /evaluation; drug design /synthesis /production; major histocompatibility complex; molecular dynamics; peptide chemical synthesis; protein structure function; receptor binding; thermodynamics

DESCRIPTION: (Adapted from the applicant's abstract) Viral diseases have, for a number of reasons, eluded the sorts of broadly effective antibiotic treatments available for bacteria, and relatively few can be prevented by vaccinations. The long-term goal of this project is to design and produce soluble, high affinity T cell receptors (TcR) or TcR-like proteins (e.g., antibodies) targeting clinically important Major Histocompatibility Complexes (MHC)-peptide structure. Such TcR or TcR-like molecules can be used directly for in vitro diagnostics of viral infection, and can be combined with toxins to kill virally infected cells specifically. The goal of Phase I of this project is to apply recently developed computational methods for binding free energy minimization to the design of high affinity TcR for MHC-peptide complexes. The computational algorithms and software implemented and validated in Phase I will be used to design novel TcR sequences, which will be produced in Phase II of the project. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：（改编自申请人摘要）病毒性疾病有，为a